Grants and Contributions:
Title:
Elarex VSV and Adv Viral Vector Vaccines Stabilization
Agreement Number:
1009921
Agreement Value:
$320,000.00
Agreement Date:
Jun 1, 2023 - Jun 30, 2024
Description:
Stabilization of multiple viral vector platforms with PT120-D to produce strong preclinical evidence of impact.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burlington, Ontario, CA L7L 4X5
Reference Number:
172-2023-2024-Q2-1009921
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
756228474
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Amendment Date
Nov 16, 2023
Recipient's Operating Name:
Elarex
Recipient's Legal Name:
ELAREX INC.
Federal Riding Name:
Burlington
Federal Riding Number:
35015
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: